IRIS Institutional Research Information System - OPENBS Open Archive UniBS

PAGNESI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.699
AS - Asia 3.078
EU - Europa 1.407
SA - Sud America 787
Continente sconosciuto - Info sul continente non disponibili 95
AF - Africa 84
OC - Oceania 7
Totale 9.157
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.501
SG - Singapore 1.071
CN - Cina 715
BR - Brasile 638
IT - Italia 509
HK - Hong Kong 414
BD - Bangladesh 281
VN - Vietnam 241
DE - Germania 179
FR - Francia 147
GB - Regno Unito 144
RU - Federazione Russa 101
TR - Turchia 99
CA - Canada 92
FI - Finlandia 69
IN - India 62
AR - Argentina 53
JP - Giappone 40
PL - Polonia 39
NL - Olanda 35
ZA - Sudafrica 34
MX - Messico 33
ES - Italia 28
IE - Irlanda 28
SA - Arabia Saudita 26
UA - Ucraina 25
AT - Austria 23
ID - Indonesia 23
IQ - Iraq 22
EC - Ecuador 21
CO - Colombia 20
SE - Svezia 14
CL - Cile 13
CR - Costa Rica 13
HN - Honduras 13
PY - Paraguay 13
VE - Venezuela 13
PK - Pakistan 12
EG - Egitto 11
MA - Marocco 11
CZ - Repubblica Ceca 10
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
EE - Estonia 8
JM - Giamaica 8
TN - Tunisia 8
KE - Kenya 7
PE - Perù 7
AZ - Azerbaigian 6
BO - Bolivia 6
GT - Guatemala 6
LT - Lituania 6
LV - Lettonia 5
MD - Moldavia 5
SV - El Salvador 5
TT - Trinidad e Tobago 5
AU - Australia 4
IL - Israele 4
IR - Iran 4
JO - Giordania 4
NI - Nicaragua 4
NP - Nepal 4
OM - Oman 4
PA - Panama 4
PH - Filippine 4
PS - Palestinian Territory 4
RS - Serbia 4
SC - Seychelles 4
AL - Albania 3
BA - Bosnia-Erzegovina 3
GR - Grecia 3
HU - Ungheria 3
KZ - Kazakistan 3
NO - Norvegia 3
PR - Porto Rico 3
SN - Senegal 3
UY - Uruguay 3
AM - Armenia 2
AO - Angola 2
BB - Barbados 2
BS - Bahamas 2
CH - Svizzera 2
CW - ???statistics.table.value.countryCode.CW??? 2
GE - Georgia 2
GP - Guadalupe 2
KG - Kirghizistan 2
KH - Cambogia 2
LK - Sri Lanka 2
MY - Malesia 2
NZ - Nuova Zelanda 2
RO - Romania 2
AI - Anguilla 1
BG - Bulgaria 1
BW - Botswana 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
FJ - Figi 1
Totale 9.047
Salva come PNG Salva come JPEG
Città #
Singapore 528
Hong Kong 411
Ashburn 404
San Jose 390
Council Bluffs 255
Beijing 199
The Dalles 174
New York 149
Los Angeles 139
Columbus 101
Lauterbourg 99
Ho Chi Minh City 96
Dallas 94
Milan 79
Istanbul 76
Santa Clara 71
Chandler 67
Munich 56
São Paulo 55
Redondo Beach 54
Chicago 49
North Bergen 49
Moscow 48
Phoenix 48
Hanoi 46
Boardman 44
Buffalo 44
Romola 44
Rome 39
San Francisco 39
London 38
Tokyo 37
Helsinki 36
Brooklyn 32
Frankfurt am Main 32
Montreal 29
Orem 29
Shanghai 29
Dublin 28
Brescia 27
Princeton 25
Warsaw 24
Atlanta 23
Denver 23
Boston 21
Nuremberg 19
Poplar 19
Guangzhou 16
Johannesburg 16
Lappeenranta 16
Toronto 16
Chennai 15
Haiphong 15
Mexico City 15
Amsterdam 14
Brasília 14
Stockholm 14
Washington 14
Düsseldorf 13
Houston 13
Las Vegas 13
Turku 13
Charlotte 12
Rio de Janeiro 12
Riyadh 12
Naples 11
Quito 11
Vienna 11
Ankara 10
Changsha 10
Curitiba 10
Salt Lake City 10
San José 10
Tianjin 10
City of London 9
Manaus 9
Ribeirão Preto 9
Turin 9
Biên Hòa 8
Newark 8
Philadelphia 8
Belo Horizonte 7
Da Nang 7
Hangzhou 7
Manchester 7
Medellín 7
New Delhi 7
North Charleston 7
Querétaro 7
Strasbourg 7
Tashkent 7
Thái Bình 7
Asunción 6
Baku 6
Bologna 6
Brno 6
Buenos Aires 6
Campina Grande 6
Campinas 6
Caracas 6
Totale 4.949
Salva come PNG Salva come JPEG
Nome #
2024 update in heart failure 197
Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG-HF 133
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 127
Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care 126
Transcatheter edge-to-edge mitral valve repair for post-myocardial infarction papillary muscle rupture and acute heart failure: A systematic review 125
Ventilation strategies in cardiogenic shock: Insights from the AltShock-2 registry 119
Characteristics and outcomes of patients with tricuspid regurgitation and advanced heart failure 118
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study 113
Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk 113
Sex differences in pulmonary arterial hypertension: Insights from the FOCUS-PAH registry 111
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 111
Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELP-HF registry 110
Right heart failure and mortality in patients undergoing transcatheter tricuspid valve interventions 108
Congestion in Patients with Advanced Heart Failure: Assessment and Treatment 108
Telemedicine for the treatment of heart failure: new opportunities after COVID-19 107
Organ perfusion pressure predicts outcomes in cardiogenic shock patients 105
Clinical Impact of Renal Dysfunction in Patients with Severe Tricuspid Regurgitation and Chronic Heart Failure 104
Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors 104
Impact of malnutrition in patients with severe heart failure 104
Decongestion and Outcomes in Patients Hospitalized for Acute Heart Failure: Insights From the RELAX-AHF-2 Trial 101
Prognostic significance of serum potassium in patients hospitalized for acute heart failure 98
Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: Insights from the HELP-HF registry 98
Combined pre- and post-capillary pulmonary hypertension in left heart disease 97
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials 97
High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis? 95
Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF 95
Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC 94
Vericiguat for Heart Failure with Reduced Ejection Fraction 94
Predicting survival in patients with severe heart failure: Risk score validation in the HELP-HF cohort 93
Prognostic value of right ventricular longitudinal strain in patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair 92
Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study 92
Heart failure: an update from the last years and a look at the near future 92
April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure 92
Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry 91
Cardiac contractility modulation: an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction? 91
Right ventricular thrombosis: from a case report to pathophysiology mechanisms and current treatment options 91
Safety and Efficacy Intravenous Istaroxime up to 60 hours for Patients with Pre-Cardiogenic Shock 90
Predictors of optimal procedural result after transcatheter edge-to-edge mitral valve repair in secondary mitral regurgitation 90
Effects of anti-inflammatory therapy in acute heart failure: a systematic review and meta-analysis 90
Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure 89
Characteristics, Prognosis and ESC/ERS Risk Stratification in Obese Patients with Pulmonary Arterial Hypertension (PAH) 87
Clinical and prognostic implications of heart failure hospitalization in patients with advanced heart failure 87
Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality 87
Towards a phenotype profiling of the patients with heart failure and preserved ejection fraction 86
Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials 86
Malnutrition and outcomes in patients with tricuspid regurgitation undergoing transcatheter tricuspid valve repair 86
Blood pressure and intensive treatment up-titration after acute heart failure hospitalization: Insights from the STRONG-HF trial 85
Predictors and Clinical Impact of Prosthesis-Patient Mismatch After Self-Expandable TAVR in Small Annuli 85
Prognostic role of tricuspid annular plane systolic excursion/pulmonary artery systolic pressure ratio in patients hospitalized for acute heart failure 84
Functional Mitral Regurgitation and Heart Failure With Preserved Ejection Fraction: Clinical Implications and Management 84
GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis 83
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure 81
Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment 81
Clinical burden and predictors of non-cardiovascular mortality and morbidity in advanced heart failure 81
Acute Heart Failure: Transitioning From Symptom-Based Care to Remission 81
Incidence, Predictors, and Prognostic Impact of New Permanent Pacemaker Implantation After TAVR With Self-Expanding Valves 80
Multimodality imaging in the diagnostic management of concomitant aortic stenosis and transthyretin-related wild-type cardiac amyloidosis 80
Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial 78
Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists 78
Burst steroid therapy and quality of life in patients with acute heart failure: Insights from the CORTAHF trial 77
Remote pulmonary artery pressure-guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC 77
Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients with Pre Cardiogenic Shock 76
NT-proBNP and high-intensity care for acute heart failure: the STRONG-HF trial 76
Mapping of current practices of palliative care for patients with heart failure throughout Europe: A scoping review 75
Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction 75
Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis 74
Medical therapy for heart failure with preserved ejection fraction: Still a minefield, but with new hope 73
Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX-AHF-2 trial 72
Performance of risk stratification scores and role of comorbidities in older vs younger patients with pulmonary arterial hypertension 72
Deep phenotype characterization of hypertensive response to exercise: implications on functional capacity and prognosis across the heart failure spectrum 72
Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction 72
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial 72
Aetiological phenotypes of atrial and ventricular secondary tricuspid regurgitation and their prognostic implications: insights from the CARE-TR registry 71
Prediction of Mortality and Heart Failure Hospitalization After Transcatheter Tricuspid Valve Interventions: Validation of TRISCORE 71
Assessing aortic flow with doppler echocardiography in cardiogenic shock: A crucial diagnostic tool 71
Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP-HF registry 70
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial 70
Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF 70
Ischemic Etiology in Advanced Heart Failure: Insight from the HELP-HF Registry 70
Detailed Assessment of the "I Need Help" Criteria in Patients With Heart Failure: Insights From the HELP-HF Registry 69
Phenotype and outcomes according to loop diuretic use in pulmonary arterial hypertension 69
Impact of SGLT2 inhibitors on endothelial function and echocardiographic parameters in dilated cardiomyopathy 69
Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF 69
March 2021 at a glance: focus on epidemiology, prevention and COVID-19 68
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: a sub-analysis of the STRONG-HF randomized clinical trial 67
Pre-admission beta-blocker therapy and outcomes in cardiogenic shock: Insights from the Altshock-2 Registry 64
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial 64
Lactate Values and Mortality in Patients With Cardiogenic Shock: Insights From the Altshock-2 Registry 63
Corticosteroid burst therapy in patients with acute heart failure: Design of the CORTAHF pilot study 63
Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial 62
Changes in Liver Function Tests, Congestion, and Prognosis After Acute Heart Failure: The STRONG-HF Trial 62
Left Main Spontaneous Coronary Artery Dissection: Clinical Features, Management, and Outcomes 61
Differences between cardiogenic shock related to acute decompensated heart failure and acute myocardial infarction 61
Insights on prevalence and incidence of anemia and rapid up-titration of oral heart failure treatment from the STRONG-HF study 59
Early changes in renal function during rapid up-titration of guideline-directed medical therapy following an admission for acute heart failure 59
February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy 58
Increasing Evidence Supports the Benefits of Rapid Uptitration of the Neurohormonal Blockade in HFmrEF/HFpEF Patients With AHF 58
Is it NICE to measure natriuretic peptides after a hospitalization for heart failure? 57
Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype 57
Noncardiac comorbidities and intensive up-titration of oral treatment in patients recently hospitalized for heart failure: insights from the STRONG-HF trial 57
Totale 8.557
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.224
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.224
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202236 0 0 0 0 2 1 2 0 2 0 3 26
2022/2023206 23 21 4 6 15 56 2 16 26 1 13 23
2023/2024622 27 11 52 33 30 71 42 17 150 21 43 125
2024/20251.864 13 22 81 152 144 140 203 94 161 225 370 259
2025/20264.817 440 595 355 677 411 282 527 228 346 361 334 261
2026/20271.612 262 189 372 789 0 0 0 0 0 0 0 0
Totale 9.157